Abstract

Vaccines developed against SARS-CoV-2 have proven to be highly effective in preventing symptomatic infection. Similarly, prior infection with SARS-CoV-2 has been shown to provide substantial protection against reinfection. However, it has become apparent that the protection provided to an individual after either vaccination or infection wanes over time. Waning protection is driven by both waning immunity over time since vaccination or initial infection, and the evolution of new variants of SARS-CoV-2. Both antibody and T/B-cells levels have been investigated as potential correlates of protection post-vaccination or post-infection. The activity of antibodies and T/B-cells provide some potential insight into the underlying causes of waning protection. This review seeks to summarise what is currently known about the waning of protection provided by both vaccination and/or prior infection, as well as the current information on the respective antibody and T/B-cell responses.

MeSH

Cells, Vaccines, Vaccination, Covid-19, Immunity, Immunity, Innate, B-Lymphocytes, Infections

Cited by

• Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study. PLoS Med, 2023
• Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine. iScience, 2024
• Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis. Vaccines (Basel), 2024
• Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis. Front Med (Lausanne), 2025
• The role of immune suppression in COVID-19 hospitalization: clinical and epidemiological trends over three years of SARS-CoV-2 epidemic. Front Med (Lausanne), 2023
• Changes in the Adaptive Cellular Repertoire after Infection with Different SARS-CoV-2 VOCs in a Cohort of Vaccinated Healthcare Workers. Vaccines (Basel), 2024
• Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana. Exp Biol Med (Maywood), 2025
• Persistence and decay of neutralizing antibody responses elicited by SARS-CoV-2 infection and hybrid immunity in a Canadian cohort. Microbiol Spectr, 2025
• Differential reactivity of SARS-CoV-2 S-protein T-cell epitopes in vaccinated versus naturally infected individuals. Clin Transl Immunology, 2025
• Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population. Vaccines (Basel), 2025
• Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia. J Med Virol, 2025
• Clinical and Preclinical Methods of Heat-Stabilization of Human Vaccines. Mol Pharm, 2024
• Recent Vaccination Against SARS-CoV-2 Is Associated with Less Severe Disease in Working-Age Adults. Int J Environ Res Public Health, 2024
• The protective effect of emergency fourth-dose vaccination issued to county-level hospital nurses against the Omicron infection peak: evidence from China. BMC Nurs, 2025
• Healthcare workers' willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo. Hum Vaccin Immunother, 2024
• Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern. Vaccines (Basel), 2025
• Project NextGen: Developing the Next Generation of COVID-19 Vaccines and Therapeutics to Respond to the Present and Prepare for the Future. Clin Infect Dis, 2024
• A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria. NPJ Vaccines, 2023
• Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques. PLoS Pathog, 2025
• Deletion of the Envelope gene attenuates SARS-CoV-2 infection by altered Spike localization and increased cell-to-cell transmission. bioRxiv, 2025